Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial


Creative Commons License

Wong K. S. L. , Amarenco P., Albers G. W. , Denison H., Easton J. D. , Evans S. R. , ...Daha Fazla

STROKE, cilt.49, ss.1678-1685, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 49 Konu: 7
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1161/strokeaha.118.020553
  • Dergi Adı: STROKE
  • Sayfa Sayıları: ss.1678-1685

Özet

Background and Purpose SOCRATES (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor with aspirin in patients with acute cerebral ischemia, found a nonsignificant 11% relative risk reduction for stroke, myocardial infarction, or death (P=0.07). Aspirin intake before randomization could enhance the effect of ticagrelor by conferring dual antiplatelet effect during a high-risk period for subsequent stroke. Therefore, we explored the efficacy and safety of ticagrelor versus aspirin in the patients who received any aspirin the week before randomization.